Losartan versus enalapril in dogs asymptomatic carriers of myxomatous degeneration of mitral valve

Abstract

The myxomatous mitral valve degeneration (DMVM) is the most common heart disease in dogs. The treatment of congestive heart failure (CHF) from DMVM is based on the use of angiotensin-converting enzyme inhibitors (ACE inhibitor) Receptor antagonists of angiotensin II (ARBs) promote complete blockade of angiotensin II, and are used in the treatment of CHF in humans, but is not common in dogs. The objective of this research was to compare the clinical responses of dogs carriers DMVM treated with enalapril-ACE inhibitors, losartan-ARBs. Thirteen dogs with DMVM and ICC class Ib were randomized into two groups as follows: G1-enalapril and G2-losartan. On physical examination, electrocardiogram and blood pressure were measured on days 0, 14, 28 and 56 after the begging of treatment. Radiographic measure, Vertebral Heart Size-VHS and ecodopplercardiográficas variables were obtained on days 0 and 56. Data were subjected to analysis of variance with repeated measures. There was no difference (P>0.05) for ecodopplercardiográficas, electrocardiographic and radiographic variables between the groups studied. In relation to time, there was a decrease (P <0.05) of the VHS, duration of the P wave and the QRS complex variables. We conclude that losartan acts similarly to enalapril in the initial treatment (first 56 days) of dogs with DMVM class Ib and II of the CHF.

Keywords

• enalapril
• endocardiosis
• losartan
• vasodilators